Therma Bright Adds Hero LifeCare as Northeast Venowave Distribution Partner
Therma Bright Adds Hero LifeCare as Northeast Venowave Distribution Partner
Hero LifeCare will initially use the nine (9) temporary CMS CPT and HCPCS codes that other U.S. distribution partners are currently using, while the Company awaits CMS approval on the permanent CPT and HCPCS.Toronto, Ontario--(Newsfile Corp. - September 13, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has signed Hero LifeCare (herolifecare.com) to be a U.S. distribution partner for marketing and selling the Venowave device.
安大略省多倫多-(Newsfile Corp.-2023年9月13日)-Therma Bright Inc.(TSXV：THRM)(場外交易市場代碼：TBRIF)(以下簡稱“Therma”或“公司”)今天宣佈，該公司已與Hero LifeCare(herolifecare.com)簽約，成為Venowave設備營銷和銷售的美國分銷合作夥伴。
Hero LifeCare ("Hero"), a large healthcare and emergency device and solutions company, together with its subsidiary Rapid Oxygen, manufacturers and markets innovative healthcare and emergency response products, including the R15, an FDA cleared first aid emergency oxygen device developed in conjunction with the University of Michigan and designed to be placed next to a fire extinguisher or AED. The new distributor sees the Venowave presenting sales opportunities to its current and growing customer base similar to the R15.
Hero LifeCare(“Hero”)是一家大型醫療保健和應急設備及解決方案公司，與其子公司Rapid O2一起，製造和營銷創新的醫療保健和應急產品，包括FDA批准的與密歇根大學合作開發的急救應急氧氣設備R15，設計放置在滅火器或AED旁邊。新的分銷商認為Venowave為其目前和不斷增長的客戶群提供了類似於R15的銷售機會。
"We're excited to welcome Hero LifeCare as our distribution partner for our Venowave device,'' continued Rob Fia. "This partner has deep connections and relationships with large medical and healthcare practices, as well as direct to consumer opportunities through its e-commerce site - herolifecare.com. Hero seeks innovative health tech solutions to help their patients and customers address a variety of health-related issues and/or symptoms, which led to the meeting of our two companies. They believe the Venowave will present another innovative medical solution to their clients to further expand their product offerings and growth."
“我們很高興地歡迎Hero LifeCare作為我們Venowave設備的分銷合作夥伴，”Rob FIA繼續說，“這個合作夥伴與大型醫療保健機構有著深厚的聯繫和關係，並通過其電子商務網站herolifecare.com直接獲得消費者機會。英雄尋求創新的健康技術解決方案，以幫助他們的患者和客戶解決各種與健康相關的問題和/或癥狀，這導致了我們兩家公司的會面。他們相信，Venowave將為他們的客戶提供另一種創新的醫療解決方案，以進一步擴大他們的產品供應和增長。“
Hero LifeCare will initially use the nine (9) temporary CMS CPT and HCPCS codes that other U.S. distribution partners are currently using, while the Company awaits CMS approval on the permanent CPT and HCPCS.
Hero LifeCare最初將使用其他美國分銷合作夥伴目前正在使用的九(9)個臨時CMS CPT和HCPCS代碼，同時公司將等待CMS對永久CPT和HCPCS的批准。
The Company looks forward to providing more information as it becomes available on expanding its distribution partners across the U.S. for its Venowave device and the unique permanent CPT and HCPCS codes process.
該公司期待著在其Venowave設備和獨特的永久CPT和HCPCS編碼過程中擴大其在美國的分銷合作夥伴方面提供更多資訊。
About Hero LifeCare
Hero LifeCare ("Hero") focuses on developing and marketing technologically advanced products, devices, and software to improve emergency response, safety, and healthcare. Hero manufactures and distributes third party innovative healthcare and emergency response products through its direct salesforce and online at herolifecare.com. Hero's subsidiary Rapid Oxygen Company, manufactures the R15, a first aid oxygen generator developed in conjunction with the University of Michigan and located in schools, airports, workplaces, convention centers, government buildings, and homes. The emergency oxygen device does not require a prescription and may be located anywhere, used by anyone, anytime. Hero is also developing the Smart Hero Station, which is intended to significantly improve public safety and provide a smart response to emergencies.
關於英雄生活護理
英雄生命護理(“英雄”)專注於開發和營銷技術先進的產品、設備和軟體，以改善應急回應、安全和醫療保健。Hero通過其直銷團隊和herolifecare.com在線製造和分銷第三方創新的醫療保健和應急產品。英雄的子公司快速氧氣公司製造R15，這是一種與密歇根大學合作開發的急救氧氣發生器，位於學校、機場、工作場所、會議中心、政府大樓和家庭。這種應急氧氣裝置不需要處方，可以放置在任何地方，任何人都可以隨時隨地使用。英雄還在開發智慧英雄站，旨在顯著提高公共安全，並提供對緊急情況的智慧反應。
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .
關於Therma Bright Inc.
Therma Bright是一家領先的專有診斷和醫療設備技術的開發商和合作夥伴，致力於為消費者和醫療專業人員提供高質量的創新解決方案，以應對當今一些最重要的醫療和保健挑戰。Therma Bright Inc.在多倫多證券交易所(TSXV：THRM)(場外交易市場代碼：TBRIF)(紐約證券交易所代碼：JNX)交易。參觀：。
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Therma Bright Inc.
羅布·菲亞，首席執行官
郵箱：rfia@thermabright.com
Follow us on Twitter
關注我們的推特
FORWARD-LOOKING STATEMENTS
前瞻性陳述
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as the commercialization and sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
本新聞稿中的某些陳述構成“前瞻性”陳述。這些陳述涉及未來的事件，如新聞稿中描述的Venowave和相關技術的商業化和銷售。所有這些陳述都涉及大量已知和未知的風險、不確定因素和其他因素，這些風險、不確定因素和其他因素可能導致實際結果與這些前瞻性陳述明示或暗示的結果大不相同。前瞻性陳述涉及重大風險和不確定因素，不應被解讀為對未來業績或結果的保證，也不一定是能否實現此類結果的準確跡象。由於幾個因素和風險，實際結果可能與預期大不相同。儘管本新聞稿中包含的前瞻性陳述是基於公司管理層認為本新聞稿發佈之日的合理假設，但公司不能向投資者保證實際結果將與這些前瞻性陳述一致。本新聞稿中包含的前瞻性陳述是自本新聞稿發佈之日起作出的，除非適用的證券法規另有要求，否則公司不會因為新資訊、未來事件或其他原因而更新或修改任何前瞻性陳述的意圖或義務。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。
